HYDROCHLOROTHIAZIDE; TRIAMTERENE | A201407 | LANNETT CO INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Lannett Company, Inc. - Citizen Petition FDA-2012-P-0142 · 3 docket documents Lannett Company, Inc. submitted this citizen petition under Section 505(j) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA Commissioner determine that a supplement to ANDA 201407 for Triamterene and Hydrochlorothiazide Capsules may be submitted for a new dosage strength of 50 mg/ | Other | 2012-03-14 | Withdrawn | — |
Lannett Company, Inc. - Citizen Petition FDA-2012-P-0061 · 3 docket documents Lannett Company, Inc. filed this citizen petition under Section 505(j) of the Federal Food, Drug, and Cosmetic Act and 21 CFR Section 314.93 requesting that the FDA Commissioner determine that a supplement to the approved ANDA 201407 for Triamterene and Hydrochlorothiazide Capsules USP 37.5 mg/25 mg | Other | 2012-01-24 | Withdrawn | — |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.1205
per ea
Lowest NADAC/Unit
$0.1205
per ea
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 62135052990TRIAMTERENE-HYDROCHLOROTHIAZIDE 37.5-25 MG CP | $0.1205 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.